✉ Email this page to a colleague
« Back to Dashboard
▶ Start for $1
Remove trial restrictions
Tegobuvir is an investigational drug.
There have been 5 clinical trials for Tegobuvir. The most recent clinical trial was a Phase 2 trial, which was initiated on September 1st 2011.
The most common disease conditions in clinical trials are Hepatitis C, Hepatitis A, and Hepatitis. The leading clinical trial sponsors are Gilead Sciences and [disabled in preview].
Recent Clinical Trials for Tegobuvir
|GS-5885, GS-9451, Tegobuvir and Ribavirin (RBV) in Interferon Ineligible or Intolerant Subjects With Chronic Genotype 1a or 1b Hepatitis C Virus (HCV) Infection||Gilead Sciences||Phase 2|
|GS-5885, GS-9451, Tegobuvir and Ribovirin in Treatment-Experienced Subjects With Chronic Genotype 1a Or 1b Hepatitis C Virus (HCV) Infection||Gilead Sciences||Phase 2|
|Oral Antivirals (GS-5885, Tegobuvir, and/or GS-9451) With Peginterferon Alfa 2a and Ribavirin in Treatment Experienced Subjects With Chronic Genotype 1 Hepatitis C Virus Infection||Gilead Sciences||Phase 2|